High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women

Blood

Volumn 119, Issue 6, 2012, Pages 1555-1560

  Andersson, Helena M ^a   Siegerink, Bob ^b   Luken, Brenda M ^a   Crawley, James T B ^a   Algra, Ale ^b,c   Lane, David A ^a   Rosendaal, Frits R ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UTILIZATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 84856895477     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380618     Document Type: Article

References (44)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
2. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72(6): 341-348. (Pubitemid 26229974)
3. Cramer EM, Meyer D, le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that ofWeibel-Palade bodies. Blood. 1985; 66(3):710-713. (Pubitemid 15230782)
4. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel- Palade bodies of human endothelial cells. J Cell Biol. 1982;95(1):355-360. (Pubitemid 13208536)
5. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel- Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-1007. (Pubitemid 43732104)
6. Schmugge M, Rand ML, Freedman J. Platelets and von Willebrand factor. Transfus Apher Sci. 2003;28(3):269-277. (Pubitemid 36506502)
7. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost. 2005;3(11):2536-2544. (Pubitemid 41727171)
8. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006;4(6): 1396-1404.
9. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85(6):780-788. (Pubitemid 40799707)
10. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98(6):1654-1661.
11. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174. (Pubitemid 30601459)
12. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006;57: 419-436.
13. Cardiovascular diseases: Fact Sheet 317. Geneva, Switzerland: World Health Organization; 2011. http://www.who.int/mediacentre/factsheets/ fs317/en/index.html. Accessed on August 4, 2011.
14. Danesh J, Wheeler JG, Hirschfield GM, et al. Creactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397. (Pubitemid 38419992)
15. Heeringa J, Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost. 2006;4(9):1944-1949. (Pubitemid 44226773)
16. Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112(20):3080-3087. (Pubitemid 43113439)
17. Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151-2156.
18. Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100(7):736-742. (Pubitemid 29383644)
19. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635-641.
20. Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28(3):354-362.
21. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006;37(11):2672-2677. (Pubitemid 44922524)
22. Hanson E, Jood K, Karlsson S, et al. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2):275-281.
23. van Schie MC, MP DEM, Dippel DW, et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost. 2010;8(6):1424-1426.
24. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109(5):1998-2000. (Pubitemid 46348198)
25. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583-588. (Pubitemid 351418945)
26. Peyvandi F, Hollestelle MJ, Palla R, et al. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. J Thromb Haemost. 2010;8(7): 1653-1656.
27. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol. 2006;77(1):67-73. (Pubitemid 43876208)
28. Horii M, Uemura S, Uemura M, et al. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels. 2008;23(5):301-307.
29. Lip GY, Blann AD, Farooqi IS, et al. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis afteracute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2002;13(4):339-347. (Pubitemid 35001875)
30. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol. 2007;100(5): 758-763. (Pubitemid 47268262)
31. Bongers TN, de Bruijne EL, Dippel DW, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis. 2009;207(1):250-254.
32. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33(5):1202-1208. (Pubitemid 34517036)
33. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345(25):1787-1793.
34. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation. 2010;122(18):1854-1861.
35. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138(4):534-540. (Pubitemid 47063038)
36. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006;4(11): 2490-2493. (Pubitemid 44575447)
37. Kokame K, Sakata T, Kokubo Y, Miyata T. VWF-to- ADAMTS13 ratio increases with age in a Japanese population. J Thromb Haemost. 2011;9(7):1426-1428.
38. De Meyer SF, Schwarz T, Deckmyn H, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice-brief report. Arterioscler Thromb Vasc Biol. 2010;30(10): 1949-1951.
39. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600-3603.
40. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329-3334.
41. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115(8):1650-1653.
42. Hanson E, Jood K, Nilsson S, Blomstrand C, Jern C. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J Thromb Haemost. 2009;7(12):2147-2148.
43. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2010; 125(1):61-66.
44. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9(5):899-908.